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Objectives: Asthma is a chronic respiratory disease with a high burden of disease 
and a relevant Public Health problem. The active patient active involvement is cru-
cial to yield the proper disease control. The aim of the study was to assess treatment 
adherence with the combination of inhaled corticosteroids (ICS) and long-acting 
beta-2 agonists (LABA), known as ICS/LABA, in the same fixed dose combination 
inhalers, depending on the inhaler device used: pressurized metered dose inhalers 
(pMDI) or dry powder inhalers (DPI), for the treatment of asthma in a real world back-
groung. Additionally asthma exacerbations, resources consumption, and associated 
costs were recorded. MethOds: An observational, retrospective study was per-
formed. Patients aged ≥ 18 years, diagnosed with asthma, and who initiated an ICS/
LABA combination treatment during 2007-2011. Patients follow-up lasted for 3 years. 
Two treatment groups of patients were identified and assessed, depending on the 
inhaler device used: pMDI or DPI. The main measures were: adherence (posession 
drug ratio), persistence, asthma severity, ICS/LABA combinations used, exacerba-
tions, resources use and their costs (direct and indirect costs). Multivariate methods 
were used for the variables correction, with a p significance degree ‹0.05. Results: 
We included 2,082 asthma patients. Mean age 52.6 years, 65.3% female: 566 patients 
(27.2%) received an pMDI and 1,516 patients (72.8%) received an DPI. Patients who 
used and pMDI device showed a higher treatment adherence (RPM: 82.9% vs 80.8%, 
p< 0.05), fewer number of exacerbations (17.7% vs 24.9%, p< 0.001), and a lower health 
cost (€ 2,531 vs € 3,020, p< 0.001). cOnclusiOns: Despite the limitations of the study, 
patients with asthma who started an ICS/LABA therapy who were treated with an 
pMDI device had higer adherence rates, better health outcomes and lower health 
costs for the Spanish National Health System.
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Objectives: Long-term treatment adherence of patients with multiple sclerosis 
(MS) treated with injectable drugs is a general concern. Closely monitoring patients’ 
therapy adherence may be beneficial. The objective of this study was to assess treat-
ment adherence of MS patients treated with the injectable drug interferon beta-1a, 
administered with the RebiSmart system. MethOds: A retrospective observational 
study was conducted, monitoring patients’ treatment adherence with the RebiSmart 
system in their normal treatment setting. The RebiSmart is an electronic, multidose 
auto-self-injection device aimed to improve assessment of treatment adherence. It 
contains a cartridge including a weekly dose. The device can accurately record time 
and dosage of each administered injection. Patients can view their own dosing log. 
Moreover, patients’ physicians can download the information providing an objective 
record of treatment adherence. To determine treatment adherence with RebiSmart, 
anonymous patient-level data of Dutch and German patients were extracted from 
the RebiSmart systems on dosing, time, and number of administrations over a five-
year time-period. Adherence was defined as taking > 80% of the treatment doses 
according to the schedule the doctor prescribed. Results: Data was collected from 
1832 patients (81% German, 73% females, average age 40.1 years). In total, 95% of 
the cartridges were used completely, indicating low drug spillage. Over the com-
plete observational period, 91% of all doses were administered according to doctor’s 
prescription. Examining individual adherence, 83% of the patients were considered 
adherent the whole period using interferon beta-1a. Results from Dutch and German 
patients were similar. cOnclusiOns: Patients using the RebiSmart device in this 
study had a considerably higher adherence level than the approximately 60% adher-
ence indicated by previous research studying adherence of MS patients on disease-
modifying drugs. Drug spillage was low. Using an auto-injection device monitoring 
patients’ treatment behavior may positively contribute to treatment adherence. 
This should be further investigated in comparative research.
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Objectives: To identify the impact of delivery device of inhaled corticosteroids and 
long-acting β 2-agonist (ICS/LABA) on asthma medication compliance, and inves-
tigate other factors associated with poor compliance. MethOds: We conducted 
a retrospective and multicentre study based on a review of medical registries of 
asthmatic patients treated with ICS/LABA combinations (n= 2,213) whose medical 
devices were either dry powder inhalers (DPI) or pressurized metered-dose inhalers 
(pMDI). Medication compliance included persistence outcomes through 18 months 
and medication possession ratios. Data on potential confounders of treatment com-
pliance such as asthma exacerbations, comorbidities, demographic characteristics 
and healthcare resource utilization were also explored. Results: The probability of 
asthma medication compliance in case of DPI was lower compared to pMDI, which 
suggest that inhaler devices condition inhalation therapies. There were additional 
confounding factors that were considered as explanatory variables of compliance. 
A worse measure of airflow obstruction (FEV1), comorbidities and visiting the GP 
more than once per month decreased the probability of compliance. Within comor-
bidities, alcoholism was positively associated with compliance. Patients of 29-39, 
40-50 and 51-61 age groups or suffering from more than 2 exacerbations during the 
study period were more likely to comply with their medication regime. We identified 
differences among DPI devices and Accuhaler® device impacted negatively greater 
on compliance compared to other DPIs. We found that GP consultations reduced 
the probability of medication compliance for patients treated with Formoterol/
ogy laboratory standard working days. The time required to test one sample was 
timed for each methodology separately and the pertaining costs were calculated. 
The working dimension of the two technologies and of the instruments needed 
was also measured. Results: The hands-on time for SISH was 76.25% lower than 
the implementation of FISH and the dedicated spaces needed to carry out the SISH 
test was 45.27% less than FISH. Lastly, the costs of using an automated SISH system 
were lower than FISH. cOnclusiOns: As a consequence of a significant reduc-
tion of laboratory personnel working hours, medical resources used and pathology 
laboratory spaces, the use of SISH technique to identify HER2 status is a cost-saving 
alternative to FISH from the perspective of the pathology laboratory.
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Objectives: Chronic Obstructive Pulmonary Disease (COPD) is a chronic respira-
tory disease with a high burden of disease and a relevant Public Health problem. 
The active patient active involvement is crucial to yield the proper disease con-
trol. The aim of the study was to assess treatment adherence with the combi-
nation of inhaled corticosteroids (ICS) and long-acting beta-2 agonists (LABA), 
known as ICS/LABA, in the same fixed dose combination inhalers, depending 
on the inhaler device used: pressurized metered dose inhalers (pMDI) or dry 
powder inhalers (DPI), for the treatment of COPD in a real world backgroung. 
Additionally COPD exacerbations, resources consumption, and associated costs 
were recorded. MethOds: An observational, retrospective study was performed. 
Patients aged ≥ 40 years, diagnosed with COPD, and who initiated an ICS/LABA 
combination treatment during 2007-2011. Patients follow-up lasted for 3 years. 
Two treatment groups of patients were identified and assessed, depending on the 
inhaler device used: pMDI or DPI. The main measures were: adherence (posession 
drug ratio), persistence, asthma severity, ICS/LABA combinations used, exacer-
bations, resources use and their costs (direct and indirect costs). Multivariate 
methods were used for the variables correction, with a p significance degree 
‹0.05. Results: We included 1,418 COPD patients. Mean age 72.1 years, 82.7% male: 
594 patients (41.9%) received an pMDI and 824 patients (58.1%) received an DPI. 
Patients who used and pMDI device showed a higher treatment adherence (RPM: 
83.3% vs 79.9%, p< 0.05), fewer number of exacerbations (40.1% vs 48.2%, p= 0.002), 
and a lower health cost (€ 3,943 vs € 4,621, p< 0.001). cOnclusiOns: Despite the 
limitations of the study, patients with COPD who started an ICS/LABA therapy 
who were treated with an pMDI device had higer adherence rates, better health 
outcomes and lower health costs for the Spanish National Health System.
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Objectives: This study aims to identify factors associated with poor compliance 
to COPD treatment in patients receiving a fixed-dose combination (FDC) of inhaled 
corticosteroids and long-acting β 2-agonist(ICS/LABA), focusing on the importance 
of inhaler devices. MethOds: We conducted a retrospective and multicentre 
study based on a review of medical registries between 2007-2012 of COPD patients 
(n= 1,263) treated with ICS/LABA FDC, whose medical devices were either dry powder 
inhalers (DPI) or pressurized metered-dose inhalers (pMDI). Medication compli-
ance included persistence outcomes through 18 months and medication posses-
sion ratios. Data on exacerbations, comorbidities, demographic characteristics and 
healthcare resource utilization were also included as confounders of medication 
compliance. Results: The analyses revealed that COPD patients whose medication 
was delivered by a DPI were less likely to comply with their treatment compared 
to patients with pMDI, after adjusting for confounding factors, especially active 
ingredients. Younger groups of patients were less likely to comply with their medi-
cation compared to the oldest group. Smoker men were less likely to comply with 
their medication compared to women and non-smokers. Comorbidities decreased 
the probability of treatment compliance. Those patients that visited their GP once 
a month were more likely to comply with their medication regimen, however sub-
optimal compliance was more likely to occur among those patients who visited 
more than 3 times per month their GP. We also found that worsening of COPD is 
negatively associated with compliance. cOnclusiOns: According to this study, 
inhaler devices influence patients’ compliance for long-term COPD medication. We 
also found that DPIs delivering ICS/LABA FDC had a negative impact on medica-
tion compliance. Patients’ clinic and socioeconomic characteristics were associated 
with compliance.
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